Patents Examined by Jasemine C. Chambers
  • Patent number: 5882924
    Abstract: The invention relates to a process for the genetic selection in microorganisms of proteins which are capable of ligand binding, in which process a protein which is capable of ligand binding is presented extracytoplasmically and the signal of the ligand binding is passed on by signal transduction to the biosynthetic machinery of the micoorganism for the purpose of expressing a detectable and/or selectable function. In addition to this, the patent discloses microorganisms which are suitable for use in this process, as well as replicons and processes for their preparation.
    Type: Grant
    Filed: October 22, 1997
    Date of Patent: March 16, 1999
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Hans-Joachim Fritz, Frank Hennecke, Harald Kolmar
  • Patent number: 5880327
    Abstract: A non-human transgenic mammalian animal, as described above, contains an exogenous double stranded DNA sequence stably integrated into the genome of the animal, which comprises cis-acting regulatory units operably linked to a DNA sequence encoding human Factor VIII protein and a signal peptide, where the cis-acting regulatory units are active in mammary gland cells and the signal peptide is active in directing newly expressed Factor VIII into the milk of the animal. The promoter may be a milk protein promoter such as for whey acidic protein, casein, lactalbumin, or beta-lactoglobulin promoter. The transgenic mammals are preferably farm animals, for example, cows, goats, sheep, rabbits and pigs. Concurrent expression of a gene for human von Willebrand's Factor into milk may be used to stabilize newly-secreted Factor VIII.
    Type: Grant
    Filed: September 21, 1994
    Date of Patent: March 9, 1999
    Assignee: American National Red Cross
    Inventors: Henryk Lubon, William N. Drohan, William H. Velander
  • Patent number: 5879926
    Abstract: The present invention relates to an improved system for producing mature heterologous proteins, and especially hirudin, by means of yeasts comprising an expression vector containing a sequence coding for the heterologous protein. This improvement is characterized by amplification of the KEX2 gene of yeast, coding for the endoprotease yscF. The amplification is carried out either by integration of one or more copies of all or part of the KEX2 gene in the yeast genome, or by insertion of one or more copies of all or part of the KEX2 gene into the vector for expression of the heterologous protein.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: March 9, 1999
    Assignee: Transgene S.A.
    Inventors: Yves Lemoine, Martine Nguyen, Tilman Achstetter
  • Patent number: 5879905
    Abstract: A method of overproducing proteins which are initiated with an amino acid other than methionine, in which methionyl-tRNA transformylase and, optionally, the appropriate tRNA synthetase are overexpressed in a host cell.
    Type: Grant
    Filed: August 29, 1996
    Date of Patent: March 9, 1999
    Assignee: Massachusetts Institute of Technology
    Inventor: Uttam L. RajBhandary
  • Patent number: 5877159
    Abstract: A method for introducing and expressing genes in animal cells is disclosed comprising infecting said animal cells with live invasive bacteria, wherein said bacteria contain a eukaryotic expression cassette encoding said gene. The gene may encode, e.g., a vaccine antigen, an therapeutic agent, an immunoregulatory agent or a anti-sense RNA or a catalytic RNA.
    Type: Grant
    Filed: May 3, 1995
    Date of Patent: March 2, 1999
    Assignee: University of Maryland at Baltimore
    Inventors: Robert J. Powell, George K. Lewis, David M. Hone
  • Patent number: 5876988
    Abstract: The present invention discloses a selection marker free system which can be used to introduce genetic modifications in bacteria, yeasts and fungi. The system can be employed to introduce or delete desired genes or DNA fragments in the genome of the indicated host species without leaving any undesired DNA i.e. the selection marker used for selection of transformants or other DNA used for cloning. In this way strains have been developed containing only desired genes introduced at desired chromosomal sites. Similarly, desired DNA fragments have been deleted or replaced at desired sites.
    Type: Grant
    Filed: June 23, 1997
    Date of Patent: March 2, 1999
    Assignee: Gist-brocades BV
    Inventors: Gerardus Cornelius Maria Selten, Bart Willem Swinkels, Robertus Franciscus Maria Van Gorcom
  • Patent number: 5876708
    Abstract: Methods of inducing tolerance including administering to the recipient a short course of help reducing treatment or administering a short course and methods of prolonging the acceptance of a graft by administering a short course of an immunosuppressant.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: March 2, 1999
    Assignee: The General Hospital Corporation
    Inventor: David H. Sachs
  • Patent number: 5874299
    Abstract: The invention relates to transgenic non-human animals capable of producing heterologous antibodies, i.e., antibodies encoded by immunoglobulin heavy and light chain genes not normally found in the genome of that species of non-human animal. In one aspect of the invention, transgenes encoding unrearranged heterologous human immunoglobulin heavy and light chains are introduced into a non-human animal thereby forming a transgenic animal capable of producing antibodies encoded by human immunoglobulin genes. Such heterologous human antibodies are produced in B-cells which are thereafter immortalized, e.g., by fusing with an immortalizing cell line such as a myeloma or by manipulating such B-cells by other techniques to perpetuate a cell line capable of producing a monoclonal heterologous antibody.
    Type: Grant
    Filed: February 14, 1997
    Date of Patent: February 23, 1999
    Assignee: GenPharm International, Inc.
    Inventors: Nils Lonberg, Robert M. Kay
  • Patent number: 5871959
    Abstract: A method of preventing tumor cell metastasis by inhibiting the binding of hepatocyte growth factor/scatter factor ("HGF/SF") with met proto-oncogene protein is described. A method of producing HGF/SF and a cell line for the production of HGF/SF are also described. The met proto-oncogene tyrosine kinase receptor (Met) and its ligand, hepatocyte growth factor/scatter factor (HGF/SF), ordinarily constitute a paracrine signalling system in which cells of mesenchymal origin produce the ligand, which binds to the receptor that is predominantly expressed in cells of epithelial origin. The method of the present invention disrupts the Met-HGF/SF autocrine signaling that contributes to the tumorigenic process in tumors of mesenchymal origin, such as sarcomas.
    Type: Grant
    Filed: November 18, 1994
    Date of Patent: February 16, 1999
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Sing Rong, George Vande Woude, Donna L. Faletto, Ilan Tsarfaty, Marianne Oskarsson
  • Patent number: 5872154
    Abstract: A method of reducing an immune response to a recombinant adenovirus which involves co-administration of the recombinant adenovirus and a selected immune modulator. The immune modulator functions by inhibiting the formation of neutralizing antibodies and/or reducing CTL killing of the virally infected cells. The method additionally encompasses the step of re-administering the recombinant adenovirus.
    Type: Grant
    Filed: February 24, 1995
    Date of Patent: February 16, 1999
    Assignees: The Trustees of the University of Pennsylvania, The Wistar Institute of Anatomy & Biology
    Inventors: James M. Wilson, Yiping Yang, Giorgio Trinchieri
  • Patent number: 5871968
    Abstract: The striking compartmentalization of p21.sup.WAF1 expression found in normal tissues is completely abrogated in neoplastic tissues. Methods are provided for using p21.sup.WAF1 expression as a tool to assess neoplasia and to discover new drugs. A truncated p21.sup.WAF1 protein is more active than full-length p21.sup.WAF1 protein in inhibiting tumor cell growth.
    Type: Grant
    Filed: February 5, 1997
    Date of Patent: February 16, 1999
    Assignee: The Johns Hopkins University
    Inventors: Kenneth W. Kinzler, Wafik El-Deiry, Bert Vogelstein
  • Patent number: 5869036
    Abstract: The present invention is based upon the observation that the temperature sensitive phenotype of the cp45 strain of HPIV-3 correlates to a mutation in the large, or L, gene of cp45 relative to the corresponding gene in the wild-type strain. This correlation enables new vaccines directed at viruses other than HPIV-3 by combining, through genetic engineering methods, the region of the cp45 viral genome which encodes proteins responsible for replication and internal structure with the region of the genome of the target virus which encodes proteins responsible for attachment, penetration and release of the virus and virus progeny, respectfully. Moreover, it is possible to determine whether HPIV-3 or a cp45-hybrid virus is attenuated by confirming the presence or absence of mutations in its L gene.
    Type: Grant
    Filed: December 8, 1995
    Date of Patent: February 9, 1999
    Assignee: St. Louis University
    Inventors: Robert B. Belshe, Ranjit Ray
  • Patent number: 5869644
    Abstract: A new technique for generating mixtures of oligonucleotides in a single automated synthesis is taught. The method can be used to prepare mixed oligonucleotides ideally suited for creation of useful mixtures of oligo- or polypeptides or proteins. Additionally, the technique enables insertion and/or substitution and/or deletion of a nucleotide sequence at one or more sites. For protein mutagenesis, a trinucleotide can be inserted or substituted at codon boundaries. The invented technique makes possible the encoding of all possible single amino acid insertions, or any desired mixture of substitutions and insertions.
    Type: Grant
    Filed: August 8, 1996
    Date of Patent: February 9, 1999
    Assignee: The Johns Hopkins University
    Inventors: David R. Shortle, John Sondek
  • Patent number: 5869239
    Abstract: Materials and methods for homologous-recombination screening of DNA libraries constructed in a eukaryotic host and methods for homologous-recombination chromosome walking for isolating overlapping DNA sequences for building an extended physical map of a chromosomal region.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: February 9, 1999
    Assignee: Transkaryotic Therapies, Inc.
    Inventors: Douglas A. Treco, Allan M. Miller
  • Patent number: 5869037
    Abstract: The present invention provides for in vivo gene transfer to adipocytes mediated by adenovirus and, in particular, the in vivo transfer of toxic genes as a means of reducing adiposity, as well as the transfer of genes encoding angiogenic substances to induce new blood vessel growth. The present invention also provides for the in vivo gene transfer to adipocytes to supply a source of proteins to be used in the local milieu of the adipocyte tissue or to be secreted and used systemically. Further, the present invention provides for the transfer of the adipocytes to other sites within a host, following adenoviral-mediated transfer of genes to the adipocytes in vivo, to allow for the exploitation of the modified adipocytes as a transferable means for the production of protein.
    Type: Grant
    Filed: June 26, 1996
    Date of Patent: February 9, 1999
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Ronald G. Crystal, Christopher J. Magovern
  • Patent number: 5869718
    Abstract: Transgenic non-human mammals and methods of preparing such mammals are disclosed. Homologous recombination is employed to inactivate genes, particularly genes coding for neuronal intermediate filaments. These animals, whose phenotype is characterized by reduced or eliminated levels of a neuronal intermediate filament, are useful as models for studying aging, injury to the nervous system, and pathogenesis of neurodegenerative diseases. They are also useful for the screening of potential therapeutic agents.
    Type: Grant
    Filed: July 15, 1996
    Date of Patent: February 9, 1999
    Inventors: Jean-Pierre Julien, Qinzhang Zhu
  • Patent number: 5866756
    Abstract: A recombinant rodent comprises cells containing a pair of genomic dopamine transporter protein alleles, wherein at least one of said alleles is incapable of expressing endogenous dopamine transporter protein. The rodent may be a homozygote, where both of said alleles are incapable of expressing endogenous dopamine transporter protein, or the rodent may be a heterozygote, and one of said alleles expresses endogenous dopamine transporter protein. The rodent is preferably a mouse.
    Type: Grant
    Filed: October 2, 1996
    Date of Patent: February 2, 1999
    Assignee: Duke University
    Inventors: Bruno Giros, Mohamed Jaber, Marc G. Caron
  • Patent number: 5866755
    Abstract: Transgenic animals carrying a transgene comprising a nucleic acid molecule encoding protein useful for regulating the expression of genes in eukaryotic cells and organisms in a highly controlled manner are disclosed. In the regulatory system of the invention, transcription of a tet operator-linked nucleotide sequence is inhibited by a transcriptional inhibitor fusion protein composed of two polypeptides, a first polypeptide which binds to tet operator sequences and a second polypeptide which directly or indirectly inhibits transcription in eukaryotic cells. In various embodiment, the first polypeptide binds to tet operator sequences either: (i) in the absence but not the presence of tetracycline (or an analogue thereof) or (ii) in the presence but not the absence of tetracycline (or an analogue thereof). In a preferred embodiment, the transgene encoding the transcriptional inhibitor fusion protein is integrated at a predetermined location within the chromosome of the transgenic animal.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 2, 1999
    Assignees: BASF Aktiengellschaft, Knoll Aktiengellschaft
    Inventors: Hermann Bujard, Manfred Gossen
  • Patent number: 5866382
    Abstract: This invention relates to recombinant-DNA-technology. Specifically, this invention relates to new recombinant yeast strains transformed with xylose reductase and/or xylitol dehydrogenase enzyme genes. A yeast strain transformed with the xylose reductase gene is capable of reducing xylose to xylitol and consequently of producing xylitol in vivo. If both of these genes are transformed into a yeast strain, the resultant strain is capable of producing ethanol on xylose containing medium during fermentation. Further, the said new yeast strains are capable of expressing the said two enzymes. Xylose reductase produced by these strains can be used in an enzymatic process for the production of xylitol in vitro.
    Type: Grant
    Filed: November 3, 1994
    Date of Patent: February 2, 1999
    Assignee: Xyrofin Oy
    Inventors: Johan Hallborn, Merja Penttila, Heikki Ojamo, Mats Walfridsson, Ulla Airaksinen, Sirkka Keranen, Barbel Hahn-Hagerdal
  • Patent number: 5866331
    Abstract: Disclosed are methods for accurately determining the total emission intensity of a single fluorochrome, under imaging conditions, using a digital imaging fluorescence microscopy system. Also disclosed are methods for detecting and localizing probe-target molecule binding. The detection method has sufficient resolution and sensitivity to locate and detect a single target-bound probe.
    Type: Grant
    Filed: October 20, 1995
    Date of Patent: February 2, 1999
    Assignee: University of Massachusetts
    Inventors: Robert H. Singer, Andrea M. Femino